ArticleOncoimmunology2020
A
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 122 citations in OpenAlex.
- Immune killer cells treatment for previously treated stage IV NSCLC patients.Scientific reports · 2024Trial
- Single-cell analysis of TIGD genes in hepatocellular carcinoma: Prognostic value and functional characterization.Translational oncology · 2026Article
- Histomorphological and Molecular Features of Colonic Large-Cell Neuroendocrine Carcinoma in a Patient With Familial Adenomatous Polyposis: A Case Report and Review of Literature.International journal of surgical pathology · 2026Review
- A 4-cuproptosis-related lncRNA theragnostic signature predicts survival and immunotherapy response in patients with lung adenocarcinoma.Molecular and clinical oncology · 2026Article
- AI-powered IC50 prediction for p53 inhibitors drug-target interaction via hybrid graph neural networks.Journal of computer-aided molecular design · 2025Article
- m6A RNA methylation regulator-associated genes drive metastasis and immune cell infiltration in skin cutaneous melanoma.Oncology letters · 2025Article
- Identification and validation of a novel signature based on M2 macrophage co-expressed genes in bladder cancer.Translational cancer research · 2025Article
- Evaluation of two algorithms measuring homologous recombination deficiency status in prognostic assessment for treatment-naïve non-small cell lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Harnessing TAGAP to improve immunotherapy for lung squamous carcinoma treatment by targeting c-Rel in CD4+ T cells.Cancer immunology, immunotherapy : CII · 2025Article
- Genomic Profiling Reveals Immune-Related Gene Differences in Lung Cancer Patients Stratified by PD1/PDL1 Expression: Implications for Immunotherapy Efficacy.Journal of applied genetics · 2025Article
- Review
- Analysis and exploration of regulatory mechanisms and potential prognostic biomarkers in squamous cell carcinoma of the lung by expression profiling.Translational cancer research · 2025Article
- Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.Cell death discovery · 2025Article
- Review
- FOXA2 Activates RND1 to Regulate Arachidonic Acid Metabolism Pathway and Suppress Cisplatin Resistance in Lung Squamous Cell Carcinoma.The clinical respiratory journal · 2024Article
- p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications.Biomedicines · 2024Review
- Identification of Genetic Variants in Exon 4 of TP53 in Lung Carcinoma and in Silico Prediction of Their Significance.Indian journal of clinical biochemistry : IJCB · 2024Article
- Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review).Molecular and clinical oncology · 2024Review
- The endoplasmic reticulum stress-related genes and molecular typing predicts prognosis and reveals characterization of tumor immune microenvironment in lung squamous cell carcinoma.Discover oncology · 2024Article
- Cuproptosis-Related lncRNA Predict Prognosis and Immune Response of LUAD.Pharmacogenomics and personalized medicine · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor-suppressor gene tumor protein p53 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.